Encyclopedia

  • Novel fatty acid binding protein 4 (FABP4) inhibitors: Virtual screening, synthesis and crystal structure determination
  • Add time:07/23/2019         Source:sciencedirect.com

    Fatty acid binding protein 4 (FABP4) is a potential drug target for diabetes and atherosclerosis. For discovering new chemical entities as FABP4 inhibitors, structure-based virtual screening (VS) was performed, bioassay demonstrated that 16 of 251 tested compounds are FABP4 inhibitors, among which compound m1 are more active than endogenous ligand linoleic acid (LA). Based on the structure of m1, new derivatives were designed and prepared, leading to the discovery of two more potent inhibitors, compounds 9 and 10. To further explore the binding mechanisms of these new inhibitors, we determined the X-ray structures of the complexes of FABP4-9 and FABP4-10, which revealed similar binding conformations of the two compounds. Residue Ser53 and Arg126 formed direct hydrogen bonding with the ligands. We also found that 10 could significantly reduce the levels of lipolysis on mouse 3T3-L1 adipocytes. Taken together, in silico, in vitro and crystallographic data provide useful hints for future development of novel inhibitors against FABP4.

    We also recommend Trading Suppliers and Manufacturers of 5-METHOXY-1H-BENZIMIDAZOLE-2-SULFONIC ACID (cas 106135-28-8). Pls Click Website Link as below: cas 106135-28-8 suppliers


    Prev:Ultrasound-assisted synthesis of UiO-66-NHSO3H via post-synthetic modification as a heterogeneous Brønsted acid catalyst
    Next: Angiotensin I converting enzyme inhibitors containing unnatural ∝-amino acid analogues of phenylalanine)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View